Tesamorelin
GHRH analog: visceral fat reduction (FDA-approved)
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
WHAT IS TESAMORELIN?
Detailed overview
Tesamorelin (Egrifta) is a 44-amino-acid stabilised GHRH analog, FDA-approved in 2010 for HIV-associated lipodystrophy to reduce visceral adipose tissue (VAT). It stimulates the pituitary's natural GH pulses while keeping IGF-1 in the physiological range. Clinical trials showed significant visceral fat loss while subcutaneous fat and lean mass were preserved or improved.
Type
GHRH analog (modified)
Structure
trans-3-hexenoyl-hGRF(1-44)NH₂
Molecular weight
~5135 Da
Target area
Visceral fat (HIV lipodystr.)
Storage
2–8°C (reconstituted)
Stability
~7 days (per label)
Growth hormone release
The peptide acts on pituitary GHRH or GHS receptors, producing a **physiological, pulsatile GH release**, unlike synthetic rHGH, which keeps levels flat and leads to desensitization. IGF-1 rises into the upper-normal range, driving recovery, muscle protein synthesis, lipolysis and skin quality. Deep-sleep phases lengthen; collagen and bone-matrix synthesis activate. The effect is reversible and does not suppress the endogenous GH axis.
Metabolic support
Glucose and lipid metabolism shift favorably: insulin sensitivity improves, glycemic swings and HbA1c drop, while LDL and triglycerides normalize. Body composition refines, fat mass decreases, lean mass is preserved or grows. Appetite is regulated both centrally and peripherally (GLP-1 / GIP / glucagon pathways), so caloric intake settles into a sustainable range without constant willpower. Energy expenditure and thermogenesis rise modestly.
Data console
Lab data
Research indications
Investigated uses and mechanisms
Growth hormone release
Mimics physiological pulsatile GH secretion; IGF-1 rise.
Recovery & body comp
Muscle mass gain, fat reduction, post-workout recovery.
Sleep quality
Deep-sleep (N3) phases lengthen.
Reconstitution
How to prepare, step by step
Important
Sterile technique required. Use bacteriostatic water (BAC) only. Never distilled or tap water.
- 01
Remove the vial and bacteriostatic water (BAC) from refrigeration; let them reach room temp for 5 minutes.
- 02
Wipe both vial stoppers with an alcohol swab.
- 03
Draw 2 ml of BAC water into a sterile syringe (typical for the 2 mg vial).
- 04
Inject slowly down the side of the vial, do NOT spray directly onto the peptide powder.
- 05
Swirl gently in a circular motion until dissolved (~30 s), do not shake.
- 06
Wait for the solution to become clear. If sediment or discoloration appears, discard it.
- 07
Label the vial with reconstitution date and concentration.
- 08
Store at 2–8 °C, protected from light. Inspect visually before each use.
Quality indicators
How to recognize a pure peptide
Purity markers
3Clear oil
Clear or slightly yellow (MCT/sesame/castor oil), particle-free.
Vial integrity
Glass intact, rubber stopper undamaged, aluminum crimp tight.
Label + COA
Manufacturer + LOT + expiry legible; independent HPLC analysis on active content.
Use caution
1BA/BB carrier blend
Excessive benzyl alcohol (>3%) raises PIP risk; verify with UGL manufacturers.
Do not use
2Cloudiness / sediment
Floating particles, cloudiness, or sediment = HARD NO.
Damaged glass / stopper
Cracked vial or loose stopper, sterility compromised.
Interactions & stacks
What to combine and what to avoid
Retatrutide
SynergisticTriple incretin agonist: metabolic health and weight loss
CJC-1295
SynergisticGHRH analog: sustained growth hormone stimulation
Ipamorelin
SynergisticGHRH + GHRP, classic pulsatile GH stack.
Vitamin C / Zinc / B-complex
SynergisticSupports collagen synthesis and antioxidant capacity.
Caffeine
Requires timingCompatible with morning dosing; avoid late-day stacking.
Insulin
Use cautionContinuous glucose monitoring required.
NSAIDs (Ibuprofen, ASA)
Use cautionLong-term concurrent use may blunt regenerative effects.
Alcohol
AvoidReduces recovery and increases side-effect risk.
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Water retention, mild edema
- Wrist / joint stiffness (carpal-tunnel-like)
- Transient blood-glucose increase
- Mild prolactin / cortisol increase (some peptides)
- PIP (post-injection pain) – especially propionate, trenbolone-ace, or high-BA blends
- Injection-site reaction: lumps, redness, warmth, tenderness
Contraindications · 5
- Pregnancy and breastfeeding
- Active malignancy
- Known allergy to the peptide or its components
- Severe hepatic or renal impairment (medical consultation required)
- Age under 18
Related Peptides
Same therapeutic category
Studies
Related research and clinical findings
Spotlight on tesamorelin in HIV-associated lipodystrophy.
Dhillon S
26 weeks of tesamorelin significantly reduced visceral adipose tissue with a favourable lipid profile change.
Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
Falutz J, Allas S, Mamputu JC, et al.
Tesamorelin produces sustained VAT reduction and favourable metabolic effects over 52 weeks with good tolerability.
Telegram
Have a question about Tesamorelin?
Reach out to an advisor on Telegram. We can help you find the right peptide.
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.